| | Generic (trade) names | Target gene or receptor | Indication |
| | IV antiangiogenic drugs | | Bevacizumab (Avastin) | VEGF-A | Metastatic colorectal cancer (mCRC) (with chemotherapy)
Metastatic NSCLC (with chemotherapy)
Metastatic breast cancer (with chemotherapy)
Recurrent glioblastoma (monotherapy)
Metastatic renal cell carcinoma (RCC) (with IFN-a) | | VEGF Trap (Aflibercept) | VEGF A, PIGF | mCRC (second-line) | | Temsirolimus (Toricel) | mTOR | Advanced RCC |
| | Oral antiangiogenic drugs | | Dasatinib (Syrcell) | BCR-ABL | Philadelphia chromosome-positive (Ph+) CML | | Imatinib (Gleevec) | BCR-ABL | Ph+ CML; gastrointestinal stromal tumor (GIST) | | Nilotinib (Tasigna) | BCR-ABL | Ph+ CML | | Bosutinib (Bosulif) | BCR-ABL, Src | Ph+ CML | | Ponatinib (Iclusig) | BCR-ABL | ALL and CML | | Vemurafenib (Zelboraf) | BRAFV600E | Melanoma | | Vismodegib (Erivedge) | SMO | Basal cell carcinoma | | Ruxolitinib (Jakafi) | JAK1/2 | Myelofibrosis | | Gefinitib (Iressa) | EGFR | NSCLC | | Erlotinib (Tarceva) | EGFR | NSCLC and pancreatic cancer | | Crizotinib (Xalkori) | EML4-ALK | NSCLC | | Abiraterone (Zytiga) | CYP17A1 | Prostate cancer | | Enzalutamide (Xtandi) | AR | Prostate cancer | | Regorafenib (Stivarga) | VEGFR2, PDGFR, FGFRs, Tie2, RAF-1, BRAF, BRAFV600E, Abl | Metastatic colorectal cancer (refractory disease) | | Lenalidomide (Revlimid) | Anti-tumor, immunomodulatory | Multiple myeloma | | Lapatinib (Tykreb) | EGFR, HER2/neu | Breast cancer | | Sunitinib (Sutent) | VEGFRs, PDGFR, VEGF, cKIT, RET, CSF-1R, flt3 | GIST; advanced RCC; Unresectable locally advanced or metastatic pancreatic neuroendocrine tumours | | Sorafenib (Nexavar) | VEGFR, PDGFR, C-Raf, B-Raf, MAP Kinase, cKIT | Advanced RCC
Unresectable hepatocellular carcinoma | | Pazopanib (Votrient) | VEGF, c-kit, PDGFR | RCC; advanced soft tissue sarcoma chemotherapy treated | | Vandetanib | VEGFRs, EGFRs and RET | Unresectable locally advanced or metastatic medullary thyroid cancer | | Everolimus (Afinitor) | mTOR | Advanced HER2-negative Breast Cancer, Progressive Neuroendocrine Tumours of Pancreatic Origin (PNET),
Subependymal Giant Cell Astrocytoma (SEGA),
Advanced RCC; soft tissue sarcoma; renal angiomyolipoma |
|
|
VEGFR, vascular endothelial growth factor receptor; NSCLC, non-small cell lung cancer; BCR-ABL, fusion of abelson (Abl) tyrosine kinase gen at chromosome 9 and break point cluster (Bcr) gene at chromosome 22; CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; EML4-ALK, rearrangement of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; HER2/neu, one of four membrane proteins in EGFR family; PDGFG, platelet-derived growth factor receptor RET: proto-oncogene, encodes receptor kinase for the neurotrophic factor family; CSF-1R, colony stimulating factor; flt3, encodes receptor tyrosine kinase that regulates hematopoiesis; MAP kinase, family of serine threonine proteins responsible for regulating cellular activities, such as apoptosis; c-kit, tyrosine kinase stem cell factor receptor; SMO, smoothened, e transmembrane protein involved in Hodgebog signal transduction; mTOR, mammalian target of rapamycin inhibitor; BRAF, gene encoding for B-Raf, member of raf kinase family.
|
